  INTRODUCTION: The Response Evaluation Criteria in Solid Tumors (RECIST) serve
as the accepted standard to monitor treatment efficacy in lung cancer. However,
the time intervals between consecutive computerized tomography scans might be
too long to allow early identification of treatment failure. This study
examines the use of breath sampling to monitor responses to anticancer
treatments in patients with advanced lung cancer. METHODS: A total of 143
breath samples were collected from 39 patients with advanced lung cancer. The
exhaled breath signature, determined by gas chromatography/mass spectrometry
and a nanomaterial-based array of sensors, was correlated with the response to
therapy assessed by RECIST: complete response, partial response, stable
disease, or progressive disease. RESULTS: Gas chromatography/mass spectrometry
analysis identified three volatile organic compounds as significantly
indicating disease control (PR/stable disease), with one of them also
significantly discriminating PR/stable disease from progressive disease. The
nanoarray had the ability to monitor changes in tumor response across therapy,
also indicating any lack of further response to therapy. When one-sensor
analysis was used, 59% of the follow-up samples were identified correctly.
There was 85% success in monitoring disease control (stable disease/partial
response). CONCLUSION: Breath analysis, using mainly the nanoarray, may serve
as a surrogate marker for the response to systemic therapy in lung cancer. As a
monitoring tool, it can provide the oncologist with a quick bedside method of
identifying a lack of response to an anticancer treatment. This may allow
quicker recognition than does the current RECIST analysis. Early recognition of
treatment failure could improve patient care.
